aTYR PHARMA (ATYR) EBITDA Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly EBITDA Margin came in at 14076.32% in Q3 2025, down 98.84% on a QoQ basis from 7079.15% in Q1 2024.

aTYR PHARMA (ATYR) EBITDA Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has 6 years of EBITDA Margin data on file, last reported at 14076.32% in Q3 2025.

Quarterly EBITDA Margin changed N/A year-over-year to 14076.32% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 38573.68% (changed N/A YoY) and the FY2025 annual result came in at 40856.32%, down 1195674.0% from the prior year.
EBITDA Margin declined to 14076.32% in Q3 2025, from 7079.15% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 76.55% in Q4 2022 to a low of 14076.32% in Q3 2025.
A 4-year average of 6201.42% and a median of 5326.4% in 2024 frame the typical range for EBITDA Margin.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.15%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	32.54%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-35.57%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	19.75%
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-	-

Download Data